topdoctors logo
Doctors and clinicsSpecialtiesConditionsDentists

Login
Area for professionals
  • Home
  • Doctors
  • Medical Oncology
  • Medical Oncologists in Central London
  • Dr Dionysis Papadatos-Pastos

Dr Dionysis Papadatos-Pastos

Medical Oncology in Central London

MD PhD MRCP(UK)
GMC: 6146326
Book
Expert in:
Lung cancer
Mesothelioma
Immunotherapy
Clinical trials
Personalised medicine
Second medical opinion
Targeted therapy
  • Information
  • CV
  • Content
  • Reviews
  • Treatments

Clinics

Leaders in Oncology Care (LOC) - part of HCA Healthcare
  • Leaders in Oncology Care (LOC) - part of HCA Healthcare profile image

    Leaders in Oncology Care (LOC) - part of HCA Healthcare

    95-97 Harley Street LOC, Leaders in Oncology Care, Central London, W1G 6AF

Credentials

Professional experience

  • 24 years of experience
  • Consultant Medical Oncologist, The London Clinic, Central London (present)
  • Consultant Medical Oncologist, Leaders in Oncology Care (LOC), Central London (present)
  • Consultant Medical Oncologist, University College London Hospitals NHS Foundation Trust (present)
  • Consultant Medical Oncologist, Princess Alexandra Hospital NHS Foundation Trust, Harlow (present)
  • Lead for lung cancer CRUK UCL Clinical Trials Centre
  • joint lead for oncology, The Princess Alexandra Hospital
View more

Subspecialties

  • Lung cancer
  • Mesothelioma
  • Thymoma
  • Immunotherapy
  • Targeted therapies
  • Chemotherapy
View more

Professional memberships

  • Royal College of Physicians
  • Medical Defence Union
  • General Medical Council
View more

Education

  • PhD Medical Oncology University of Crete (2012)
  • Degree in Medicine Athens University (2002)

Publications and conferences

  • First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors,Clin Cancer Res . 2020 Sep 15;26(18):4777-4784
  • HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors, AACR Annual Meeting 2020; April 27-28, 2020
  • Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit, Eur J Cancer . 2017 Apr;75:56-62
  • A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors, Clin Cancer Res . 2012 May 1;18(9):2687-94
  • Combining targeted therapeutics in the era of precision medicine, Br J Cancer 2015;112:1-3
  • Delayed onset immune related adverse effects (IRAEs) of pembrolizumab in non-small cell lung cancer, 2019, ESMO Annual Meeting, 1510P
  • A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma, 2011 ASCO annual meeting
  • A first-in-human phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL), 2010 ESMO annual meeting
  • Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience. 2010 ASCO annual meeting 2010, received the ASCO foundation Merit Award.
  • A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy. Clin Oncol (R Coll Radiol). 2024 Jan 16:S0936-6555(24)00025-6. doi: 10.1016/j.clon.2024.01.009. Online ahead of print.
  • The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-533. doi: 10.1038/s41586-023-05783-5. Epub 2023 Apr 12. PMID: 37046096
  • The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023 Apr;616(7957):534-542. doi: 10.1038/s41586-023-05729-x. Epub 2023 Apr 12. PMID: 37046095
  • Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J Immunother Cancer. 2022 Jun;10(6):e004495. doi: 10.1136/jitc-2022-004495. PMID: 35717027 Free PMC article. Clinical Trial.
View more

Prizes and awards

  • ASCO (American Society of Clinical Oncology) Merit Award (2010)

Languages spoken

  • English
  • Greek
Registration number: 6146326
The doctor, or where applicable the hospital or medical centre in which the doctor provides services, undertakes to keep the information relating to the prices of services published on their profile on the Top Doctors platform up to date at all times, ensuring that such prices correspond to those effectively charged to patients. In the event of any discrepancy between the published price and the price ultimately charged to the patient, the doctor and/or the relevant hospital or medical centre shall be solely liable towards the patient and towards Top Doctors for any claim or financial difference arising therefrom.

Request now: The appointment management service is free

Appointment subject to confirmation

Leaders in Oncology Care (LOC) - part of HCA Healthcare95-97 Harley Street LOC, Leaders in Oncology Care, Central London, W1G 6AF
Payment methodSelf-paying
  • About us
  • About Top Doctors
  • Why choose us?
  • Quality commitment
  • Selection process
  • Medical Specialist Advisory Panel
  • Privacy policy
  • Terms of Use
  • Cookies policy
  • Policy on the use of third party applications
  • Quality and Environmental Policy
  • Carbon reduction plan
  • Collaborate with us
  • Doctors
  • Our Clinics
  • Strategic alliances
  • Join us
  • Top Doctors Awards
  • Nominate doctors
  • Customer services
  • Doctors by medical insurance
  • Contact us
  • FAQs
  • All medical procedures
  • Press and media
  • Press
  • Medical articles

Contact
  • Doctors
  • Member
  • Patients
Social networks
CertificatesComodo Secure
Privacy policy and Terms of Use

Top Doctors | 20-22 Wenlock Road, London, England, N1 7GU